Placing Value on FDA's Priority Review Vouchers
Executive Summary
The ability of priority review vouchers to stimulate research for neglected diseases of the developing world hinges on the vouchers having tangible value. What's the worth of a priority review voucher on the market and how does that value change depending upon the situation?
You may also be interested in...
Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
What’s a Priority Review Voucher worth? That’s a complicated question now that the first voucher used on an application, from drug maker Novartis AG for Ilaris (canakinumab), has received a complete response letter from US regulators.
Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
What’s a Priority Review Voucher worth? That’s a complicated question now that the first voucher used on an application, from drug maker Novartis AG for Ilaris (canakinumab), has received a complete response letter from US regulators.
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.